干旱区生态环境知识资源中心(Arid): Ocriplasmin for Treatment of Vitreomacular Traction: An Update

Arid

DOI	10.1007/s40123-016-0062-6
	Ocriplasmin for Treatment of Vitreomacular Traction: An Update
	Khan, Mohammed Ali; Haller, Julia A.
通讯作者	Haller, JA
来源期刊	OPHTHALMOLOGY AND THERAPY
ISSN	2193-8245
EISSN	2193-6528
出版年	2016
卷号	5 期号:2 页码:147-159
英文摘要	Pharmacologic vitreolysis with ocriplasmin, a 27 kilodalton serine protease, is an effective nonsurgical treatment option for vitreomacular traction (VMT). Data from phase III clinical studies, including the Microplasmin for Intravitreal Injection-Traction Release without Surgical Treatment (MIVI-TRUST) and Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) studies, have demonstrated the treatment efficacy of ocriplasmin for VMT and full-thickness macular hole (FTMH). Subgroup analysis of these clinical trials as well as post-marketing clinical series have aided in patient selection by identifying features associated with successful pharmacologic release of VMT with ocriplasmin, including adhesion diameter ae1500 mu m, absence of epiretinal membrane, phakic status, and age younger than 65. As a first-in-class therapeutic, ocriplasmin and its side effects have been carefully monitored by the vitreoretinal community. The following categories of related or possibly related adverse events have been identified: acute reduction in visual acuity, ERG changes, dyschromatopsia, retinal tear or detachment, lens subluxation or phacodonesis, abnormal pupillary reflex, retinal vascular changes, and OCT ellipsoid zone alterations. Adverse events have almost all been transient with restoration of visual acuity; however, in select patients, alterations may persist.
英文关键词	Macular hole Ocriplasmin Pharmacologic vitreolysis Vitreomacular adhesion Vitreomacular traction Vitreoretinal interface
类型	Review
语种	英语
开放获取类型	DOAJ Gold, Green Published
收录类别	ESCI
WOS记录号	WOS:000389469600003
WOS关键词	OPTICAL COHERENCE TOMOGRAPHY ; INTRAVITREAL OCRIPLASMIN ; MACULAR HOLE ; VISION LOSS ; MIVI-TRUST ; ADHESION ; OUTCOMES ; METAANALYSIS ; RESOLUTION ; INJECTION
WOS类目	Ophthalmology
WOS研究方向	Ophthalmology
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/331690
作者单位	[Khan, Mohammed Ali] Doheny Eye Ctr UCLA, Dept Ophthalmol, Retina Div, Pasadena, CA USA; [Khan, Mohammed Ali; Haller, Julia A.] Wills Eye Hosp & Res Inst, Retina Serv, Philadelphia, PA 19107 USA
推荐引用方式 GB/T 7714	Khan, Mohammed Ali,Haller, Julia A.. Ocriplasmin for Treatment of Vitreomacular Traction: An Update[J],2016,5(2):147-159.
APA	Khan, Mohammed Ali,&Haller, Julia A..(2016).Ocriplasmin for Treatment of Vitreomacular Traction: An Update.OPHTHALMOLOGY AND THERAPY,5(2),147-159.
MLA	Khan, Mohammed Ali,et al."Ocriplasmin for Treatment of Vitreomacular Traction: An Update".OPHTHALMOLOGY AND THERAPY 5.2(2016):147-159.